{
  "id": "treatment-resistant-depression",
  "title": "Treatment-resistant depression",
  "lang": "en",
  "source_lang": "en",
  "summary": "Treatment-resistant depression is persistent major depression despite adequate treatment trials, requiring careful reassessment and consideration of additional therapeutic approaches.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Refractory depression",
    "Therapy-resistant depression",
    "Pharmacoresistant depression",
    "TRD"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/treatment-resistant-depression/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/treatment-resistant-depression/",
      "json": "https://aiwiki.page/zh/treatment-resistant-depression.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Treatment-resistant depression (TRD) generally describes an episode of major depressive disorder that has not responded adequately to at least two antidepressant treatments given at an appropriate dose and for sufficient time. This is a widely used operational definition rather than a universally agreed biological category. Definitions differ over what constitutes an adequate trial, whether the treatments must belong to different drug classes, and whether unsuccessful psychological treatments count toward resistance. The term does not mean that recovery is impossible or that every available treatment has failed.\n\nTRD is important because persistent depressive symptoms are associated with substantial disability, impaired relationships and occupational functioning, poorer health-related quality of life, and increased risk of suicide. Its assessment involves more than counting prescriptions: diagnostic accuracy, actual medication exposure, coexisting conditions, adverse effects, and barriers to care all influence apparent treatment failure. Its management encompasses medication changes and augmentation, structured psychotherapy, electroconvulsive therapy, noninvasive brain stimulation, and ketamine-based treatments. These approaches differ in their evidence, speed of effect, durability, risks, and availability."
    },
    {
      "heading": "Definition, treatment adequacy, and staging",
      "text": "The most common definition of TRD requires inadequate benefit from two adequate antidepressant trials during the current depressive episode. However, clinical studies and regulatory frameworks do not apply this definition identically. Some require failures of two different pharmacological classes, whereas others accept two drugs from the same class. Some count only complete nonresponse; others include partial improvement that leaves clinically important symptoms. Consequently, two study populations described as treatment resistant may differ substantially in illness duration, severity, and prior treatment exposure.\n\nAn adequate medication trial involves dose, duration, and actual use. Many research definitions require at least six to eight weeks of treatment, including a meaningful interval at a therapeutic dose, although the appropriate evaluation period depends on the drug and clinical circumstances. A prescription that was stopped early because of adverse effects does not demonstrate the same phenomenon as sustained treatment without benefit. Likewise, irregular use, unaffordable prescriptions, or a dose that never reached the intended range can produce apparent resistance. The term pseudoresistance describes such situations, although it can obscure the genuine clinical importance of intolerance and access barriers.\n\nTreatment outcomes are usually distinguished as response, remission, and recovery. Response commonly means a reduction of at least 50% on a validated depression rating scale. Remission means that symptoms fall below a specified threshold; it does not necessarily imply restoration of normal functioning. Recovery generally refers to remission sustained over time, but its duration varies across studies. The Hamilton Depression Rating Scale, Montgomery–Åsberg Depression Rating Scale, and other instruments quantify symptom changes, while a patient-reported outcome can capture experiences that clinician ratings may miss.\n\nSeveral staging systems describe resistance as a continuum rather than a yes-or-no state. The Thase–Rush model, introduced in the 1990s, emphasizes successive failures of antidepressant classes and electroconvulsive therapy. The Maudsley Staging Method incorporates treatment history, episode duration, and symptom severity. These systems support research description but do not reliably identify which treatment will work for an individual. The broader concept of difficult-to-treat depression emphasizes persistent illness burden despite usual treatment efforts, including obstacles beyond pharmacological nonresponse. None of these labels establishes a single underlying disease mechanism or an irreversible prognosis."
    },
    {
      "heading": "Diagnostic reassessment and apparent resistance",
      "text": "A careful diagnostic assessment distinguishes persistent unipolar depression from conditions that can resemble it or alter its treatment. Bipolar disorder is particularly important because depressive episodes may precede recognized mania or hypomania. A history of unusually elevated or irritable mood, reduced need for sleep, increased activity, and associated functional change can alter the diagnostic formulation. Psychotic symptoms, catatonia, substance-related disorders, and cognitive disorders also affect interpretation of an unsuccessful antidepressant trial. Resistance cannot be understood accurately without establishing what condition was being treated.\n\nThe medical history provides a chronology of episodes, medications, psychological treatments, adherence, benefits, adverse effects, and reasons for discontinuation. Medical records and pharmacy information can help distinguish a documented treatment failure from a recalled prescription whose dose and duration are unknown. Symptom measurement over time can reveal partial benefits obscured by an overall impression of failure. It can also separate improvement in mood from persistent sleep disturbance, cognitive complaints, or loss of functioning. These distinctions matter because different residual problems may have different causes.\n\nThe differential diagnosis includes medical disorders that cause or worsen depressive symptoms. Examples include hypothyroidism, anemia, neurological disease, and sleep disorders such as obstructive sleep apnea. Medication effects and alcohol or other substance use can contribute to fatigue, sleep disruption, cognitive impairment, and low mood. Clinical evaluation and laboratory investigation are directed by the history and examination rather than by a universal test panel capable of diagnosing TRD. No blood test or brain scan establishes treatment resistance.\n\nCoexisting psychiatric conditions are common and can independently sustain disability. Anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, and substance-use disorders may require distinct outcome measures and treatment components. Chronic pain and insomnia can remain disabling even when core depressive symptoms improve. Their presence does not invalidate a diagnosis of major depression, but attributing every continuing symptom to antidepressant resistance can conceal important contributors.\n\nAssessment also includes social context and safety. Housing instability, interpersonal violence, financial hardship, and fragmented care can perpetuate distress and interrupt treatment. These are not evidence that symptoms are less biological or less real. Evaluation of suicidal thoughts, intent, planning, previous behavior, and available support is distinct from determining the degree of treatment resistance. A depression severity score alone cannot fully characterize immediate suicide risk, and a history of medication nonresponse does not by itself determine the appropriate level of care."
    },
    {
      "heading": "Frequency, illness course, and consequences",
      "text": "Estimates of TRD frequency depend heavily on the population studied and the definition used. Surveys of people reporting depressive symptoms, specialist-clinic samples, insurance records, and prospective treatment studies measure different phenomena. A prescription database can identify repeated medication changes but may not establish diagnosis, adherence, dose adequacy, or clinical response. Specialist services disproportionately include people with severe or longstanding illness. Thus, the prevalence of TRD cannot be represented reliably by a single percentage applicable to every health system or population.\n\nA frequently cited source is the US Sequenced Treatment Alternatives to Relieve Depression study, known as STAR*D, whose principal results appeared in 2006. It enrolled more than 4,000 outpatients with major depression and offered successive treatment steps after an initial trial of citalopram. Approximately one-third achieved remission during the first step, depending on the outcome measure and analysis. Remission generally became less likely after additional unsuccessful steps. The study demonstrated that further treatment could still help after an initial failure, while also documenting the difficulty of achieving sustained wellness with successive interventions.\n\nSTAR*D does not provide a simple population estimate of permanent resistance. Later treatment steps involved selected participants who continued in the study, and attrition complicated interpretation. Its frequently quoted cumulative remission estimate of about two-thirds reflects a particular analysis across sequential steps, not the proportion of all initially enrolled participants observed to remain well over the long term. The study was also conducted before several currently available interventions became established. It remains influential as a large, practical investigation of sequential treatment rather than a complete map of contemporary outcomes.\n\nPersistent depression affects concentration, memory, motivation, sleep, physical activity, and social participation. These effects can interfere with education, employment, caregiving, and relationships. Medical comorbidity may further complicate the course; depression can coexist with diabetes mellitus, cardiovascular disease, and other chronic conditions. Associations between TRD and higher healthcare use, hospitalization, and costs are consistently reported, but observational comparisons cannot always separate the effects of treatment resistance from greater illness severity and other underlying differences.\n\nTRD is also associated with elevated suicide-related morbidity and mortality. Individual outcomes nevertheless vary widely. Some people remit after a later intervention, others experience recurrent episodes separated by periods of recovery, and others have persistent symptoms with fluctuating severity. Long episode duration, greater symptom burden, anxiety, and multiple previous failures are associated with poorer average outcomes, but none determines an individual course. Treatment resistance is best understood as a description of the illness and treatment history at a particular point, not a prediction that future treatment will fail."
    },
    {
      "heading": "Biological mechanisms and the search for predictors",
      "text": "There is no established biological lesion that distinguishes all cases of TRD from treatment-responsive depression. Major depression is heterogeneous, and resistance may arise through several interacting pathways. Conventional antidepressants influence signaling involving serotonin, norepinephrine, and, for some agents, dopamine. Their effects do not establish that depression is simply a deficiency of one neurotransmitter. Clinical benefit usually develops more slowly than their immediate pharmacological actions, directing research toward downstream changes in neural communication, stress regulation, and adaptation.\n\nOne major research framework concerns neuroplasticity, the capacity of neural systems to change their function and connections. Stress-related changes in synaptic signaling, reward processing, and cognitive control may contribute to persistent symptoms. Glutamate signaling and proteins involved in synaptic maintenance have received particular attention following the antidepressant effects of ketamine. These findings support investigation of mechanisms beyond traditional monoamine targets. However, mechanisms demonstrated in animal experiments or inferred from small human studies cannot automatically be treated as established explanations for clinical resistance.\n\nNeuroimaging research has examined networks involving the prefrontal cortex, anterior cingulate cortex, hippocampus, and other regions involved in emotion and cognition. Functional magnetic resonance imaging measures patterns of blood-oxygenation change associated with neural activity. Studies have linked different patterns of connectivity to symptoms and treatment outcomes, and connectivity information is being investigated for stimulation targeting. Most findings are group-level associations. They do not yet constitute a widely validated diagnostic scan that identifies TRD or reliably selects the best treatment for each patient.\n\nStress physiology and inflammation are additional areas of investigation. Some people with depression have altered activity of the hypothalamic–pituitary–adrenal axis or elevated inflammatory markers. However, these changes are neither universal nor specific to TRD. Inflammatory measurements are influenced by infection, body composition, smoking, sleep, and other medical conditions. An association between an inflammatory marker and poor response does not establish that inflammation caused treatment failure or that an anti-inflammatory drug will improve depression.\n\nA clinically useful biomarker must provide reproducible information that improves decisions beyond ordinary clinical assessment. Genetic variants affecting drug-metabolizing enzymes can influence medication exposure, and pharmacogenomic tests sometimes inform questions about metabolism or drug interactions. They do not identify a universally effective antidepressant or explain most treatment resistance. Prediction models combining clinical information, imaging, genetics, and other measurements remain an active research area. Their clinical value depends on independent validation, representative populations, and evidence that using the model improves meaningful outcomes."
    },
    {
      "heading": "Antidepressant changes and pharmacological augmentation",
      "text": "Pharmacological strategies after an unsuccessful antidepressant trial include optimization, switching, combination treatment, and augmentation. Optimization addresses whether the existing treatment has been adequately delivered and tolerated. Switching replaces one antidepressant with another, either within the same class or across classes. Combination treatment uses more than one antidepressant, whereas augmentation adds an agent whose principal use may lie outside depression treatment. These strategies differ conceptually, but actual practice often involves overlapping medication changes that make attribution of benefit difficult.\n\nCommon antidepressant groups include selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors, alongside agents with other mechanisms. Switching across classes does not guarantee better results than switching within a class. Older antidepressants remain relevant in selected circumstances but have distinct safety burdens. Tricyclic drugs can cause anticholinergic effects, orthostatic hypotension, and cardiac toxicity; monoamine oxidase inhibitors have important drug interactions and, for some preparations, dietary restrictions. These considerations affect suitability independently of potential efficacy.\n\nAmong augmentation approaches, several second-generation antipsychotics have evidence from controlled trials, and some have regulatory authorization as adjunctive treatments for major depression. Aripiprazole, quetiapine extended release, and brexpiprazole are examples, although approved indications vary by jurisdiction. Benefits must be interpreted alongside adverse effects such as akathisia, sedation, weight gain, and metabolic changes. The use of an antipsychotic as an adjunct does not imply that the depressive episode includes psychosis. Its pharmacological effects can be relevant to mood symptoms without a psychotic disorder.\n\nLithium augmentation has a longstanding evidence base, particularly from studies involving older antidepressants. Its use involves measurement of blood concentrations and attention to kidney and thyroid function, interactions, and toxicity. Triiodothyronine, a thyroid hormone, has also been investigated as an augmentation agent. The evidence supporting different options is uneven: some treatments have numerous short-term randomized trials, while others rely on smaller or older studies. Evidence that lithium may reduce suicide in mood disorders is distinct from evidence about its antidepressant augmentation effect, and estimates vary across study designs.\n\nComparative trials illustrate both the potential and limitations of later-step medication treatment. In the 2017 VAST-D trial, involving predominantly male US veterans, 12-week remission occurred in approximately 22% after switching to bupropion, 27% with bupropion augmentation, and 29% with aripiprazole augmentation. Aripiprazole augmentation produced a modest remission advantage over switching, alongside a different adverse-effect profile. These results do not establish a universal sequence for every person with TRD: the population, previous treatment history, tolerability, and duration of follow-up limit generalization."
    },
    {
      "heading": "Psychological treatments and persistent functional impairment",
      "text": "Psychotherapy can address depressive symptoms, patterns of avoidance, interpersonal difficulties, and the consequences of prolonged illness. Medication nonresponse does not establish that psychological treatment will fail, because the interventions engage different processes. Conversely, psychotherapy is not evidence that persistent depression results from insufficient effort or mistaken thinking alone. Trials examine specific, structured treatments delivered with a defined intensity; their findings cannot automatically be generalized to every form of supportive contact or counseling.\n\nCognitive behavioral therapy has substantial evidence as an additional treatment when depression persists despite medication. It combines work on patterns of interpretation with changes in behavior, activity, and coping. The UK CoBalT trial, published in 2013, compared usual care with usual care plus cognitive behavioral therapy in primary-care patients whose depression had not responded adequately to antidepressants. At six months, about 46% of participants assigned to added therapy met the trial’s response criterion, compared with about 22% receiving usual care alone. Its entry definition was broader than the strict requirement of two documented adequate medication failures.\n\nOther relevant approaches include behavioral activation, interpersonal psychotherapy, and therapies developed for chronic depression. The Cognitive Behavioral Analysis System of Psychotherapy was specifically designed for chronic depressive presentations and emphasizes interpersonal consequences of behavior. These therapies differ in theoretical emphasis, therapist training, and evidence base. Chronic depression and TRD overlap but are not interchangeable: a long-lasting episode may have received little adequate treatment, while a shorter episode may already have failed several well-documented interventions.\n\nPsychological treatment research presents particular methodological challenges. Participants and therapists usually know which treatment is being delivered, so full blinding is generally impossible. Comparison conditions differ in therapist time, expectations, and access to other care. Dropout, therapist expertise, and treatment fidelity can influence outcomes. These limitations do not negate observed benefits, but they affect comparisons with medication trials and interpretation of which components produced improvement. Follow-up after treatment is especially important because a brief symptom change may not represent durable recovery.\n\nFunctional restoration is a separate dimension of care and research. Reduced symptom scores may coexist with impaired concentration, social withdrawal, unemployment, or difficulty resuming ordinary responsibilities. Rehabilitation, occupational support, sleep-focused interventions, and treatment of coexisting conditions can address these domains. Progress may be measured through participation, relationships, and daily activities as well as mood ratings. Such outcomes are relevant even when complete remission has not occurred, but they should not be used to obscure continuing depressive symptoms or lack of access to effective treatment."
    },
    {
      "heading": "Electroconvulsive therapy",
      "text": "Electroconvulsive therapy (ECT) induces a controlled cerebral seizure through electrical stimulation under general anesthesia and muscle relaxation. Introduced by Ugo Cerletti and Lucio Bini in 1938, it has undergone major changes in anesthesia, electrical delivery, monitoring, and technique. Contemporary ECT differs substantially from unmodified procedures used early in its history. It is an established treatment for severe depression and is particularly relevant when symptoms are life-threatening, psychotic, or accompanied by catatonia.\n\nECT is often considered in TRD, but it is not limited to people who have exhausted numerous medications. Urgency, previous response, depressive features, and medical circumstances can justify its use earlier in an episode. It commonly has greater short-term efficacy than further conventional medication treatment in severe depression, although outcomes vary by population. Higher response rates in psychotic depression and lower rates after extensive treatment failure illustrate why a single success percentage is misleading. The distinction between response and remission is especially important in interpreting published estimates.\n\nAn acute course usually consists of repeated treatments over several weeks. Electrode placement, pulse width, electrical dose relative to seizure threshold, and treatment frequency influence both effectiveness and cognitive adverse effects. Right unilateral and bilateral techniques have different efficacy–tolerability trade-offs, and technical parameters matter within each category. ECT affects distributed brain networks and several neurochemical processes; no single mechanism fully explains its antidepressant effects. The occurrence of a seizure alone does not describe all the factors determining therapeutic benefit.\n\nImportant adverse effects include transient confusion, headache, muscle discomfort, and memory disturbance. Difficulties forming new memories generally improve after the treatment course, while loss of autobiographical memories around the treatment period can be more persistent. The extent varies with individual susceptibility and treatment technique. Anesthetic and cardiovascular risks are assessed separately from cognitive effects. Assessment of decision-making capacity, informed consent, and applicable legal safeguards is central because severe depression can affect decision-making without automatically eliminating capacity.\n\nRelapse after a successful acute course is a major limitation. Continuation medication, continuation ECT, or combinations are used to preserve benefit, but relapse can still occur. Studies therefore distinguish acute remission from sustained recovery. ECT research also faces practical challenges in choosing comparison treatments and measuring memory over time. Access depends on trained staff, anesthesia services, facilities, and transportation, and public understanding remains influenced by historical practices and cultural portrayals that do not accurately represent all contemporary treatment."
    },
    {
      "heading": "Transcranial magnetic stimulation and other stimulation methods",
      "text": "Transcranial magnetic stimulation (TMS) uses a changing magnetic field to induce electrical activity in the brain without inducing a generalized seizure as its intended therapeutic mechanism. Repetitive TMS for depression usually targets prefrontal regions connected to mood-regulation networks. It does not ordinarily require anesthesia, and participants remain awake during treatment. In the United States, the first TMS device received clearance for major depression in 2008; subsequent devices and protocols have differed in their authorized populations and treatment parameters.\n\nConventional repetitive TMS commonly involves sessions on most weekdays over several weeks. High-frequency stimulation over the left dorsolateral prefrontal cortex is a well-studied approach, while other protocols use right-sided low-frequency or bilateral stimulation. Target location, coil design, intensity, pulse pattern, and total treatment exposure can affect outcomes. Sham-controlled trials support antidepressant efficacy, but response is not universal, and comparisons across studies are complicated by differences in prior treatment resistance and treatment technique.\n\nIntermittent theta-burst stimulation delivers brief bursts in a patterned sequence and can substantially shorten individual sessions. The 2018 THREE-D trial found that a three-minute intermittent theta-burst protocol was noninferior to a conventional 37.5-minute high-frequency protocol under the trial’s conditions. This finding concerned two specified protocols, not all brief and conventional stimulation methods. Accelerated schedules deliver multiple sessions per day, sometimes with individualized imaging-based targeting. Their evaluation includes not only rapid symptom change but also durability, retreatment needs, resource requirements, and reproducibility outside specialist centers.\n\nCommon TMS adverse effects include scalp discomfort and headache. Seizures are rare but recognized, and implanted devices or particular neurological circumstances can affect eligibility. TMS generally has fewer direct cognitive adverse effects than ECT, but it does not reproduce ECT’s evidence across all severe depressive presentations. Some people continue medication during TMS, making the intervention an addition rather than a replacement. Maintenance and retreatment schedules are less standardized than acute courses, and long-term comparative evidence remains an important area of study.\n\nOther stimulation methods have more limited or specialized roles. Vagus nerve stimulation uses an implanted device to stimulate a cervical nerve; it received US authorization in 2005 for certain adults with chronic or recurrent depression after multiple treatment failures. Its effects generally develop over months, and surgery, device management, and voice-related adverse effects are relevant. Deep brain stimulation directly stimulates surgically implanted brain targets but remains investigational for depression, with mixed controlled-trial results. Transcranial direct current stimulation is also under study, with evidence and regulatory status differing across settings."
    },
    {
      "heading": "Ketamine and esketamine",
      "text": "Ketamine is an anesthetic drug whose antidepressant effects at lower-than-anesthetic exposure prompted a major shift in depression research. A small randomized study published in 2000 and a subsequent controlled trial in TRD published in 2006 demonstrated that symptoms could improve within hours rather than only after several weeks. Ketamine is a racemic mixture of two molecular forms, or enantiomers. Esketamine, the S-enantiomer, has been developed as an intranasal medicine. Formulation, route, dose exposure, and regulatory indication distinguish these treatments.\n\nKetamine blocks N-methyl-D-aspartate receptors, which participate in glutamate signaling. Proposed downstream mechanisms involve altered activity in neural circuits, increased signaling through other glutamate receptors, and changes in synaptic plasticity. The relative contribution of these processes in humans remains under investigation. Rapid symptom improvement does not establish that all relevant mechanisms are immediate, nor that the benefits will persist after a single administration. Laboratory findings concerning synapses and growth-related proteins support hypotheses rather than a complete explanation of clinical response.\n\nIntravenous racemic ketamine is used off-label for depression in several jurisdictions. Intranasal esketamine received US approval in 2019 for TRD in adults in conjunction with an oral antidepressant; in 2025 its US indication expanded to permit monotherapy for TRD. Authorization and reimbursement differ internationally. In the United States, esketamine is administered under a restricted safety program with supervised dosing and post-administration observation because of risks including sedation, dissociation, respiratory depression, and misuse.\n\nShort-term effects can include perceptual changes, dissociation, dizziness, nausea, sedation, and increased blood pressure. With unsupervised or repeated nonmedical ketamine use, dependence and urinary tract injury are recognized concerns. The frequency and significance of long-term harms under medically supervised antidepressant regimens require assessment separately from patterns of heavy nonmedical use. Maintenance studies provide information beyond single-dose experiments, but treatment discontinuation, selection of initial responders, and varying schedules complicate estimates of durability.\n\nKetamine-based treatment has also been studied for rapid reduction of suicidal ideation. Improvement in reported suicidal thoughts is not equivalent to proof that suicide attempts or deaths are prevented. Esketamine’s indication for depressive symptoms in adults with major depression and acute suicidal ideation or behavior is distinct from its TRD indication, and neither should be interpreted as establishing suicide prevention. Studies comparing ketamine with ECT have also depended on population selection; findings in nonpsychotic TRD do not automatically apply to psychotic depression, catatonia, or all urgent clinical presentations."
    },
    {
      "heading": "Long-term outcomes, evidence limitations, and access to care",
      "text": "TRD research increasingly separates short-term symptom improvement from sustained recovery. Acute studies often last only a few weeks, whereas the illness may continue or recur over years. Relevant outcomes include remission, relapse, functioning, cognitive effects, adverse events, treatment burden, and quality of life. A treatment that produces rapid benefit but requires frequent supervised visits presents a different long-term profile from one with slower effects and simpler delivery. Discontinuation effects and return of the underlying illness must also be distinguished when symptoms reappear after treatment stops.\n\nMaintenance evidence is often generated through randomized-withdrawal designs. People who respond to an initial treatment are assigned either to continue it or to receive a comparison condition. Such studies can establish whether continuation reduces relapse among initial responders, but they do not directly estimate effectiveness in everyone who starts treatment. Selection of responders, treatment discontinuation, and the possibility that participants recognize their assignment can influence interpretation. These issues are especially important for interventions with noticeable subjective effects or intensive clinical contact.\n\nThe quality of evidence depends on study design as well as statistical significance. A randomized controlled trial can reduce confounding, but small samples, incomplete follow-up, inconsistent definitions, and selective reporting still matter. Clinical endpoints differ: a modest change in an average rating score is not the same as remission or restored functioning. Comparisons across separate trials are less reliable than direct comparisons because participants may have different illness severity, numbers of previous failures, and coexisting conditions. Long-term observational studies add information but cannot eliminate all differences between treatment groups.\n\nAccess shapes both measured resistance and real-world outcomes. Psychotherapy requires trained clinicians and time; ECT requires anesthesia and specialized facilities; TMS and esketamine involve repeated visits; implanted stimulation adds surgical and device-related costs. Insurance rules may require documentation of particular previous treatments before authorizing another intervention. Rural location, transport, employment conditions, caregiving, and out-of-pocket expenditure can determine whether an adequate course is feasible. These social determinants of health can generate treatment failure that is partly a property of care delivery rather than drug efficacy.\n\nShared decision-making provides a framework for comparing uncertain benefits, adverse effects, cognitive concerns, treatment burden, and personal priorities without assuming that symptom scores capture every relevant outcome. Research priorities include more representative recruitment, consistent definitions of treatment adequacy, direct comparisons of treatment sequences, and follow-up long enough to assess sustained benefit. Studies increasingly examine adaptive treatment strategies and prediction tools, but a clinically useful approach must demonstrate improved outcomes rather than merely classify participants accurately within the dataset on which it was developed."
    }
  ],
  "links": [
    "depression",
    "health-related-quality-of-life",
    "patient-reported-outcome",
    "diagnosis",
    "bipolar-disorder",
    "medical-history",
    "differential-diagnosis",
    "hypothyroidism",
    "anemia",
    "anxiety-disorders",
    "post-traumatic-stress-disorder",
    "obsessive-compulsive-disorder",
    "chronic-pain",
    "insomnia",
    "prevalence",
    "diabetes-mellitus",
    "cardiovascular-disease",
    "serotonin",
    "norepinephrine",
    "dopamine",
    "neuroplasticity",
    "hippocampus",
    "functional-magnetic-resonance-imaging",
    "inflammation",
    "biomarker",
    "pharmacogenomics",
    "hormone",
    "psychotherapy",
    "cognitive-behavioral-therapy",
    "blinding-clinical-trials",
    "rehabilitation",
    "anesthesia",
    "decision-making-capacity",
    "randomized-controlled-trial",
    "clinical-endpoint",
    "social-determinants-of-health",
    "shared-decision-making"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}